These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 12227555)

  • 1. Morphological changes of Candida albicans induced by micafungin (FK463), a water-soluble echinocandin-like lipopeptide.
    Nishiyama Y; Uchida K; Yamaguchi H
    J Electron Microsc (Tokyo); 2002; 51(4):247-55. PubMed ID: 12227555
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro antifungal activity of FK463, a new water-soluble echinocandin-like lipopeptide.
    Mikamo H; Sato Y; Tamaya T
    J Antimicrob Chemother; 2000 Sep; 46(3):485-7. PubMed ID: 10980180
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glucan-associated protein modulations and ultrastructural changes of the cell wall in Candida albicans treated with micafungin, a water-soluble, lipopeptide antimycotic.
    Angiolella L; Maras B; Stringaro AR; Arancia G; Mondello F; Girolamo A; Palamara AT; Cassone A
    J Chemother; 2005 Aug; 17(4):409-16. PubMed ID: 16167521
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro activities of a new lipopeptide antifungal agent, FK463, against a variety of clinically important fungi.
    Tawara S; Ikeda F; Maki K; Morishita Y; Otomo K; Teratani N; Goto T; Tomishima M; Ohki H; Yamada A; Kawabata K; Takasugi H; Sakane K; Tanaka H; Matsumoto F; Kuwahara S
    Antimicrob Agents Chemother; 2000 Jan; 44(1):57-62. PubMed ID: 10602723
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro antifungal activity of a novel lipopeptide antifungal agent, FK463, against various fungal pathogens.
    Uchida K; Nishiyama Y; Yokota N; Yamaguchi H
    J Antibiot (Tokyo); 2000 Oct; 53(10):1175-81. PubMed ID: 11132964
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of FK463, a (1,3)-beta-D-glucan synthase inhibitor, in disseminated azole-resistant candida albicans infection in mice.
    Maesaki S; Hossain MA; Miyazaki Y; Tomono K; Tashiro T; Kohno S
    Antimicrob Agents Chemother; 2000 Jun; 44(6):1728-30. PubMed ID: 10817741
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Micafungin (FK463) on Candida albicans adherence to epithelial cells.
    Borg-von Zepelin M; Zaschke K; Gross U; Monod M; Müller FM
    Chemotherapy; 2002 Jul; 48(3):148-53. PubMed ID: 12138332
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FK463, a novel water-soluble echinocandin lipopeptide: synthesis and antifungal activity.
    Tomishima M; Ohki H; Yamada A; Takasugi H; Maki K; Tawara S; Tanaka H
    J Antibiot (Tokyo); 1999 Jul; 52(7):674-6. PubMed ID: 10513849
    [No Abstract]   [Full Text] [Related]  

  • 9. Effect of the growth medium on the in vitro antifungal activity of micafungin (FK-463) against clinical isolates of Candida dubliniensis.
    Müller FM; Kurzai O; Hacker J; Frosch M; Mühlschlegel F
    J Antimicrob Chemother; 2001 Nov; 48(5):713-5. PubMed ID: 11679561
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The efficiency of the benzothiazole APB, the echinocandin micafungin, and amphotericin B in fluconazole-resistant Candida albicans and Candida dubliniensis.
    Melkusová S; Bujdáková H; Volleková A; Myoken Y; Mikami Y
    Pharmazie; 2004 Jul; 59(7):573-4. PubMed ID: 15296100
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Candida albicans and Candida dubliniensis respond differently to echinocandin antifungal agents in vitro.
    Jacobsen MD; Whyte JA; Odds FC
    Antimicrob Agents Chemother; 2007 May; 51(5):1882-4. PubMed ID: 17307974
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antifungal mechanism of FK463 against Candida albicans and Aspergillus fumigatus.
    Hatano K; Morishita Y; Nakai T; Ikeda F
    J Antibiot (Tokyo); 2002 Feb; 55(2):219-22. PubMed ID: 12003006
    [No Abstract]   [Full Text] [Related]  

  • 13. Overexpression of Candida albicans CDR1, CDR2, or MDR1 does not produce significant changes in echinocandin susceptibility.
    Niimi K; Maki K; Ikeda F; Holmes AR; Lamping E; Niimi M; Monk BC; Cannon RD
    Antimicrob Agents Chemother; 2006 Apr; 50(4):1148-55. PubMed ID: 16569823
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel echinocandin antifungals. Part 2: Optimization of the side chain of the natural product FR901379. Discovery of micafungin.
    Tomishima M; Ohki H; Yamada A; Maki K; Ikeda F
    Bioorg Med Chem Lett; 2008 May; 18(9):2886-90. PubMed ID: 18424132
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative study of disc diffusion and microdilution methods in susceptibility testing of micafungin against Candida species.
    Ramírez M; Serrano MC; Castro C; López E; Almeida C; Fernández A; Romero A; Martín-Mazuelos E
    J Antimicrob Chemother; 2006 Oct; 58(4):861-3. PubMed ID: 16916868
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activities of micafungin against 315 invasive clinical isolates of fluconazole-resistant Candida spp.
    Messer SA; Diekema DJ; Boyken L; Tendolkar S; Hollis RJ; Pfaller MA
    J Clin Microbiol; 2006 Feb; 44(2):324-6. PubMed ID: 16455878
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of FK463, a new lipopeptide antifungal agent, in mouse models of disseminated candidiasis and aspergillosis.
    Ikeda F; Wakai Y; Matsumoto S; Maki K; Watabe E; Tawara S; Goto T; Watanabe Y; Matsumoto F; Kuwahara S
    Antimicrob Agents Chemother; 2000 Mar; 44(3):614-8. PubMed ID: 10681327
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum differentially alters the antifungal properties of echinocandin drugs.
    Paderu P; Garcia-Effron G; Balashov S; Delmas G; Park S; Perlin DS
    Antimicrob Agents Chemother; 2007 Jun; 51(6):2253-6. PubMed ID: 17420211
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The echinocandins.
    Cappelletty D; Eiselstein-McKitrick K
    Pharmacotherapy; 2007 Mar; 27(3):369-88. PubMed ID: 17316149
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Progressive loss of echinocandin activity following prolonged use for treatment of Candida albicans oesophagitis.
    Laverdière M; Lalonde RG; Baril JG; Sheppard DC; Park S; Perlin DS
    J Antimicrob Chemother; 2006 Apr; 57(4):705-8. PubMed ID: 16464893
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.